US stock · Healthcare sector · Medical Devices
C
Cerus Corporation
CERS
NASDAQ2.90
USD
+0.08
(+2.84%)
Market Closed
-11.28P/E
-18Forward P/E
-0.53P/E to S&P500
515.092MMarket CAP
- -Div Yield
Upcoming Earnings
3 May-8 May
Shares Short
2/28/23
7.68M
Short % of Float
4.47%
Short % of Shares Outs.
4.32%
% Held by Insiders
3.37%
% Held by Institutions
81.86%
Beta
0.97
PEG Ratio
- -
52w. high/low
5.95/2.36
Avg. Daily Volume
1.67M
Return %
Stock
S&P 500
1 year
(48.26)
(12.11)
3 years
(23.99)
64.73
5 years
(49.28)
50.61
Scale: |
High
Low
7.29
0.55
3.57
0.59
4.01
1.76
3.68
1.92
4.53
2.62
7.13
2.90
8.00
3.48
7.03
3.81
7.64
4.17
4.70
1.93
8.05
3.38
6.88
3.70
8.87
2.71
8.41
4.67
7.01
3.25
4.05
2.36
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
0.35
0.51
0.52
0.57
0.69
0.67
0.59
0.49
0.36
0.39
0.47
0.58
0.67
0.70
0.97
0.92
Earnings per share
(1.42)
(0.90)
(0.69)
(0.42)
(0.35)
(0.29)
(0.64)
(0.52)
(0.58)
(0.62)
(0.56)
(0.44)
(0.51)
(0.37)
(0.33)
(0.24)
FCF per share
(1.20)
(1.10)
(0.43)
(0.39)
(0.33)
(0.26)
(0.41)
(0.56)
(0.54)
(0.53)
(0.49)
(0.25)
(0.53)
(0.26)
(0.21)
(0.16)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.02
0.04
0.01
0.04
0.00
0.00
0.01
0.03
0.01
0.01
0.00
0.01
0.06
0.01
0.01
0.01
Book Value per sh.
1.88
1.06
0.62
0.59
0.38
0.35
0.63
0.56
0.99
0.57
0.36
0.64
0.41
0.63
0.52
0.38
Comm.Shares outs.
32
32
35
40
48
55
68
75
96
102
108
132
140
164
164
177
Avg. annual P/E ratio
(5.0)
(5.0)
(2.2)
(6.9)
(7.9)
(11.5)
(7.9)
(9.3)
(8.8)
(9.5)
(6.0)
(13.6)
(10.5)
(16.1)
(19.0)
(19.7)
P/E to S&P500
(0.3)
(0.2)
(0.0)
(0.3)
(0.5)
(0.8)
(0.5)
(0.5)
(0.4)
(0.4)
(0.3)
(0.5)
(0.4)
(0.4)
(0.6)
(0.9)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
11
17
18
23
33
37
40
36
34
39
51
76
94
114
160
162
Operating margin
(390.9)%
(185.0)%
(132.5)%
(69.1)%
(48.2)%
(47.1)%
(71.4)%
(122.2)%
(178.5)%
(156.5)%
(112.1)%
(72.3)%
(70.6)%
(51.1)%
(30.7)%
(21.0)%
Depreciation (m)
1
1
1
1
1
1
1
1
2
2
2
1
2
3
3
3
Net profit (m)
(45)
(29)
(24)
(17)
(17)
(16)
(43)
(39)
(56)
(63)
(61)
(58)
(71)
(60)
(54)
(43)
Income tax rate
- -
- -
- -
- -
- -
(1.5)%
(0.5)%
(0.5)%
6.2%
(0.3)%
(6.9)%
(0.4)%
(0.4)%
(0.5)%
(0.6)%
(1.2)%
Net profit margin
(410.2)%
(176.8)%
(134.2)%
(73.2)%
(51.4)%
(43.4)%
(109.3)%
(106.4)%
(163.2)%
(160.2)%
(118.0)%
(75.7)%
(76.0)%
(52.4)%
(34.1)%
(26.4)%
Working capital (m)
56
29
19
22
19
18
39
46
109
67
67
94
78
123
109
53
Long-term debt (m)
- -
- -
- -
3
5
3
- -
10
17
12
30
22
39
56
71
29
Equity (m)
60
34
21
24
18
19
43
42
95
58
39
85
57
104
85
68
ROIC
- -
- -
- -
(57.0)%
(66.0)%
(65.9)%
(97.4)%
(72.5)%
(46.2)%
(78.9)%
(76.4)%
(48.3)%
(56.6)%
(34.7)%
(31.3)%
(36.9)%
Return on capital
(57.9)%
(61.6)%
(69.1)%
(33.7)%
(35.3)%
(30.9)%
(51.1)%
(46.4)%
(41.5)%
(58.3)%
(54.6)%
(32.6)%
(39.2)%
(25.2)%
(20.8)%
(16.8)%
Return on equity
(75.6)%
(85.1)%
(112.5)%
(71.3)%
(92.7)%
(83.3)%
(101.3)%
(93.3)%
(59.0)%
(108.9)%
(155.6)%
(68.1)%
(124.9)%
(57.7)%
(64.3)%
(63.3)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
1 Mar · 2023 | Q4
All numbers in millions
Total liabilities
$ 150
Total assets
$ 218
Long-term debt
$ 29
Cash and equiv.
$ 36
Goodwill
$ 1
Retained earnings
$ (1,007)
Common stock
177
Enterprise Value
$ 508
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
134
129
102
Receivables
21
25
34
Inventory
23
27
29
Other
5
18
4
Current assets
183
187
170
Acc. Payable
24
36
33
Debt due
10
17
58
Other
25
26
26
Current liabilities
60
79
117
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
1.59%
21.59%
18.42%
Cash flow
(20.72)%
12.25%
9.83%
Earnings
(21.32)%
(5.68)%
1.64%
Dividends
- -
- -
- -
Book value
(20.10)%
2.72%
20.17%
Insider Trading
Type
Shares
Date
Moore Carol
Sale
3,350
03/13/23
Moore Carol
Sale
9,728
03/13/23
Jayaraman Vivek K
Sale
8,791
03/13/23
Jayaraman Vivek K
Sale
16,565
03/13/23
Menard Chrystal
Sale
5,758
03/13/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
25
27
29
34
114
2021
30
38
42
50
160
2022
43
48
40
32
162
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.10)
(0.09)
(0.09)
(0.09)
(0.37)
2021
(0.11)
(0.09)
(0.08)
(0.06)
(0.33)
2022
(0.07)
(0.05)
(0.05)
(0.08)
(0.24)
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. William M. Greenman
Full-time employees:
631
City:
Concord
Address:
1220 Concord Avenue
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.